home / stock / eyeg / eyeg quote
Last: | $35.32 |
---|---|
Change Percent: | 0.04% |
Open: | $35.36 |
Close: | $35.32 |
High: | $35.36 |
Low: | $35.27 |
Volume: | 6,602 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$35.32 | $35.36 | $35.32 | $35.36 | $35.27 | 6,602 | 05-17-2024 |
$35.3749 | $35.3749 | $35.3749 | $35.3749 | $35.3749 | 0 | 05-16-2024 |
$35.4205 | $35.4205 | $35.4205 | $35.4205 | $35.4205 | 3 | 05-15-2024 |
$35.1798 | $35.1798 | $35.1798 | $35.1798 | $35.1798 | 3 | 05-14-2024 |
$35.0853 | $35.0853 | $35.0853 | $35.0853 | $35.0853 | 0 | 05-13-2024 |
$35.0606 | $35.0606 | $35.0606 | $35.0606 | $35.0606 | 1 | 05-10-2024 |
$35.1632 | $35.1632 | $35.1632 | $35.1632 | $35.1632 | 1 | 05-09-2024 |
$35.0936 | $35.0936 | $35.0936 | $35.0936 | $35.0936 | 4 | 05-08-2024 |
$35.1757 | $35.1757 | $35.1757 | $35.1757 | $35.1757 | 1 | 05-07-2024 |
$35.1219 | $35.1219 | $35.1219 | $35.1219 | $35.1219 | 2 | 05-06-2024 |
$35.06 | $35.07 | $35.06 | $35.08 | $35.06 | 503 | 05-03-2024 |
$34.8718 | $34.8718 | $34.8718 | $34.8718 | $34.8718 | 0 | 05-02-2024 |
$34.705 | $34.705 | $34.705 | $34.705 | $34.705 | 1 | 05-01-2024 |
$34.6963 | $34.6963 | $34.6963 | $34.6963 | $34.6963 | 1 | 04-30-2024 |
$34.8561 | $34.84 | $34.8561 | $34.88 | $34.81 | 4,001 | 04-29-2024 |
$34.735 | $34.735 | $34.735 | $34.735 | $34.735 | 300 | 04-26-2024 |
$34.6239 | $34.61 | $34.6239 | $34.6239 | $34.61 | 300 | 04-25-2024 |
$34.722 | $34.66 | $34.722 | $34.722 | $34.66 | 5,000 | 04-24-2024 |
$34.815 | $34.815 | $34.815 | $34.815 | $34.815 | 90 | 04-23-2024 |
$34.735 | $34.734 | $34.735 | $34.735 | $34.734 | 4,000 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Eyegate Pharmaceuticals Inc. Company Name:
EYEG Stock Symbol:
NASDAQ Market:
Eyegate Pharmaceuticals Inc. Website:
LONDON, UK / ACCESSWIRE / December 9, 2022 / Kazia Therapeutics has announced the publication of pre-clinical data for its second pipeline asset, EVT801 in the journal Cancer Research Communications. The research was conducted by licensing partner Evotec and was the key driver for Kazia in-licen...
LONDON, UK / ACCESSWIRE / December 7, 2022 / With its H123 interim results, ReNeuron highlighted progress across its proprietary exosome platform, CustomEx. The company reported H123 revenues of £438k (H122: £58k), primarily related to income associated with a £320k payment from F...
WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announc...